Literature DB >> 9743084

Nitric oxide is a regulator of mucociliary activity in the upper respiratory tract.

T Runer1, A Cervin, S Lindberg, R Uddman.   

Abstract

The in vitro effects of the nitric oxide (NO) substrate L-arginine on ciliary beat frequency and the in vivo effects of the NO donor sodium nitroprusside (SNP) on mucociliary activity were investigated in the rabbit maxillary sinus mucosa with photoelectric techniques. L-Arginine increased ciliary beat frequency in vitro with a maximum response of 27.1% +/- 6.4% at 10(-3) mol/L, and this effect was reversibly blocked by pretreatment with the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine, whereas D-arginine had no such effect. SNP increased mucociliary activity in vivo, the peak response of 36.8% +/- 4.2% being obtained at the dose of 30.0 microg/kg. No tachyphylaxis was observed after repeat challenge with SNP. The increase in mucociliary activity caused by SNP was largely unaffected by pretreatment with the calcium channel blocker nifedipine, the cyclooxygenase inhibitor diclofenac, and the cholinergic antagonist atropine. The nonselective beta-blocker propranolol delayed the peak response of SNP to 7 to 8 minutes after challenge, compared with 1 to 2 minutes after challenge in animals without pretreatment. The results show the NO substrate L-arginine and the NO donor SNP to have ciliostimulatory effects in vitro and in vivo, respectively. The occurrence of NOS production in the sphenopalatine ganglion and sinus mucosa of the rabbit was studied by immunohistochemistry for NOS activity or nicotinamide adenine dinucleotide phosphate-diaphorase histochemistry. The latter is an indirect sign of neuronal NOS activity. Numerous NOS-containing cell bodies were seen in the sphenopalatine ganglion; in the sinus mucosa a moderate supply of thin NOS-immunoreactive nerve fibers was seen. Taken together, the morphologic findings and the functional results indicate NO to be a regulator of mucociliary activity in upper airways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743084     DOI: 10.1016/S0194-5998(98)70063-4

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  16 in total

Review 1.  Nasal nitric oxide in man.

Authors:  J O Lundberg; E Weitzberg
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Balloon dilation technology: let the truth be told.

Authors:  Peter J Catalano
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

3.  Computational modeling of nasal nitric oxide flux from the paranasal sinuses: Validation against human experiment.

Authors:  Barak M Spector; Dennis J Shusterman; Andrew N Goldberg; Edward M Weaver; Alexander A Farag; Bradley A Otto; Kai Zhao
Journal:  Comput Biol Med       Date:  2021-07-31       Impact factor: 6.698

Review 4.  Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise.

Authors:  Palak P Oza; Khosrow Kashfi
Journal:  Nitric Oxide       Date:  2022-08-24       Impact factor: 4.898

Review 5.  Neurogenic mechanisms in rhinosinusitis.

Authors:  J N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.919

6.  Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome.

Authors:  Steven H Abman; Nicholas R Fox; M Ibrahim Malik; Sneha S Kelkar; Shelby L Corman; Sanika Rege; Jenna Bhaloo; Rachel Shah; Ren-Jay Shei; Dana Saporito; Nisreen Shamseddine; Erik DeBoer; George J Wan
Journal:  Drugs Context       Date:  2022-04-11

7.  The mechanism of ciliary stimulation by acetylcholine: roles of calcium, PKA, and PKG.

Authors:  Orna Zagoory; Alex Braiman; Zvi Priel
Journal:  J Gen Physiol       Date:  2002-04       Impact factor: 4.086

8.  Could nasal nitric oxide help to mitigate the severity of COVID-19?

Authors:  Jan Martel; Yun-Fei Ko; John D Young; David M Ojcius
Journal:  Microbes Infect       Date:  2020-05-06       Impact factor: 2.700

9.  Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms.

Authors:  Camille Jardeleza; Shasha Rao; Benjamin Thierry; Pratik Gajjar; Sarah Vreugde; Clive A Prestidge; Peter-John Wormald
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 10.  Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy.

Authors:  Pierachille Santus; Maurizio Rizzi; Dejan Radovanovic; Andrea Airoldi; Andrea Cristiano; Rosalynn Conic; Stephen Petrou; Paolo Daniele Maria Pigatto; Nicola Bragazzi; Delia Colombo; Mohamad Goldust; Giovanni Damiani
Journal:  Biomed Res Int       Date:  2018-09-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.